The Mounjaro prescribing information (Type 2 diabetes indication) does not list it in Table 1 it appears only under postmarketing reports (Section 6.2), meaning it was reported by real people after the drug reached the market rather than captured as a statistically significant signal in the controlled T2D trials
Hypoglycemia: Assess risk in patients taking concomitant insulin or insulin secretagogues
For the efficacy estimand, the LSM change in HbA1c from baseline at week 52 as the primary endpoint was 2.24%, 2.43%, and 2.58% with tirzepatide 5, 10, and 15 mg, respectively, versus 1.44% with insulin glargine
Your treatment timeline depends largely on how well you stick to your healthy lifestyle habits while on weight loss injections
It does not directly enhance fat oxidation the way levocarnitine does, but it addresses the B12 deficiency risk that increases with reduced food intake on GLP-1 therapy